Tyzavan is the first FDA-approved vancomycin formulation available at room temperature that requires no compounding, thawing, or dilution, enabling faster treatment in time-critical infections like sepsis.
Climate change, wildfire aftermath, and lack of a reliable vaccine raise concerns that dengue may become endemic in parts of the U.S. as mosquito season intensifies.
GAMMAGARD LIQUID ERC is the first ready-to-use liquid immunoglobulin therapy with IgA ≤2 µg/mL for primary immunodeficiency in individuals aged 2 years and older.
Older Americans are embracing vaccines—backed by new research confirming enhanced safety, disease prevention, and even a potential link to reduced dementia risk.
FDA approved the first biannual injectable PrEP option, Yeztugo (lenacapavir), after studies showed it prevented HIV infection in over 99.9% of participants.